StemCell Therapy

OverviewWhat is an ophthalmologist vs an optometrist?

An ophthalmologist is an eye care specialist. Unlike optometrists and opticians, ophthalmologists are doctors of medicine (MD) or doctors of osteopathy (DO) with specific training and experience in diagnosing and treating eye and vision conditions.

An ophthalmologist is qualified to deliver total eye care, meaning vision services, eye examinations, medical and surgical eye care, and diagnosis and treatment of disease and visual complications that are caused by other conditions, like diabetes.

An ophthalmologist has completed four years of pre-medical undergraduate education, four years of medical school, one year of internship, and three or more years of specialized medical and surgical training in eye care. As a qualified specialist, an ophthalmologist is licensed by a state regulatory board to diagnose, treat, and manage conditions affecting the eye and visual system.

An ophthalmologist can take care of all your eye care needs, but you should consider working with an ophthalmologist any time you have a serious eye problem that will require surgery or specialized treatment.

Ophthalmologists perform surgery for the following eye problems:

Here are some examples of conditions when you might seek treatment from an ophthalmologist:

Regular eye screening is another thing you can do to protect your and your familys good health. Your eye health can change over time, so its a good idea to plan for regular eye examinations.

Most routine eye examinations start with questions about your eyes:

Next, your ophthalmologist will ask about your history of wearing eyeglasses or using contacts. They might also ask about your overall health and your family medical history, including any specific eye problems.

Your ophthalmologist will perform several tests to learn more about your eye health:

You might see your ophthalmologist as part of a regular checkup or for a specific eye problem. Either way, youll want to know whats happening with your eye health. Here are a few questions for you to consider:

A note from Cleveland Clinic

Protecting your eye health should be one of your personal health priorities. Few things in life are as precious as the ability to see clearly. Fortunately, there are many ways to treat common eye problems. Make your eye health a priority by having eye examinations as recommended by your ophthalmologist and seeking help anytime you notice changes in your vision.

Read more:
What is an Ophthalmologist? Definition & Types - Cleveland Clinic

If youve ever had to search for an eye care doctor, youre likely aware that there are several different types of eye specialists. Optometrists, ophthalmologists, and opticians are all professionals who specialize in eye care.

An optometrist is an eye doctor that can examine, diagnose, and treat your eyes. An ophthalmologist is a medical doctor who can perform medical and surgical interventions for eye conditions. An optician is a professional who can help fit eyeglasses, contact lenses, and other vision-correcting devices.

In this article, we will explore the education requirements, salary, scope of practice, and services that optometrists, ophthalmologists, and opticians provide. We will also discuss how to choose the best eye-care professional for your needs.

An optometrist is the primary health care provider for routine eye care.

An optometry program is a postgraduate program that takes roughly 4 years to complete, depending on the school and curriculum. The program curriculum includes:

Optometry program coursework also includes full-time clinical training as a resident during the final 1 to 2 years of the program.

In 2018, the median salary for optometrists was $111,790, according to the Bureau of Labor Statistics.

You can visit an optometrist for your yearly eye exam, to refill an eyeglass or contact prescription, or even to receive medication and treatment for certain eye conditions. Unlike an ophthalmologist, an optometrist is not a surgical specialist and cannot treat more serious eye conditions.

Optometrists provide the following services::

Optometrists can prescribe controlled medications for eye conditions. Depending on the state legislation, some optometrists can also perform minor surgeries. These surgical procedures may include foreign body removal, laser eye surgery, and certain additional surgical interventions.

An ophthalmologist is a medical doctor who specializes in surgical eye procedures.

All ophthalmologists must complete a full medical program before they can begin a residency program in ophthalmology. An ophthalmology residency program takes an additional 4 to 7 years to complete, depending on the school and curriculum. The residency program expands on:

Ophthalmology residency training also includes the hands-on care of patients, which involves performing surgical procedures under supervision. The residency program generally follows a one year internship.

In 2018, the average salary for ophthalmologists was $290,777 according to Salary.com.

You can visit an ophthalmologist for the same care as an optometrist, such as a routine eye exam or prescription refill. However, an ophthalmologist can also perform eye surgery for various diseases and conditions, including cataracts, glaucoma, and strabismus surgery, plus more.

Ophthalmologists provide the following services:

Ophthalmologists receive 12 or more years of training in order to be able to perform in-depth surgical procedures for diseases of the eyes. Given that this is their specialty, almost all ophthalmologists will focus on this as their primary scope of care.

Depending on the scope of practice within the state, both optometrists and ophthalmologists can perform eye surgery. However, optometrists are limited in the surgeries they can perform while ophthalmologists can perform any and all surgical procedures they are trained for.

An optician is a customer service representative who works in a vision care store or optometrists office.

Optician training is much more informal than optometry or ophthalmology training. An optician does not necessarily need to hold a formal degree. An optician can become certified by completing a 1- to 2-year program, such as an associates program in ophthalmic dispensing.

An optician may also become certified through an in-house apprenticeship under an ophthalmologist or optometrist.

In 2018, the median salary for opticians was $37,010 according to the Bureau of Labor Statistics.

Opticians perform customer service duties at your optometrists office or local vision care center. You can visit an optician for routine care, adjustment, and refilling of prescription eyeglasses and contact lenses.

Opticians can also answer general eye care questions, but they cannot examine, diagnose or treat diseases of the eye.

Opticians provide the following services:

Unlike optometrists and ophthalmologists, opticians are not allowed to perform any eye exams or diagnose or treat any eye conditions.

How do you know which provider you should choose for your eye care? Choosing an optometrist, ophthalmologist, or optician will depend on the service you need.

Optometrists, ophthalmologists, and opticians are all eye care professionals who differ in their education, specialty, and scope of practice.

Optometrists are basic eye care specialists who can examine, diagnose, and medically treat eye conditions. Ophthalmologists are a type of medical doctor who specialize in surgical procedures of the eye. Opticians are customer service specialists who work in vision care centers and optometry offices.

Choosing the right eye care professional for you will depend on what services you need. For a comprehensive list of optometrists near you, check out the American Optometric Associations Find a Doctor tool.

Read the original:
Optometrist vs. Ophthalmologist: Choosing Your Eye Care Provider

Ophthalmology is the study of medical conditions relating to the eye. Ophthalmologists are doctors who specialize in the medical and surgical treatment of this organ.

A general practice doctor may refer someone to an ophthalmologist if they show symptoms of cataracts, eye infections, optic nerve problems, or other eye conditions.

In this article, we look at what ophthalmologists do, including the types of conditions that they treat, the procedures they perform, and when a person might see this specialist.

An ophthalmologist is a medical doctor who specializes in diagnosing and treating eye-related conditions.

To practice in the United States, ophthalmologists must complete:

Some ophthalmologists undergo a year or two of fellowship training specializing in one of the many subspecialties of ophthalmology, such as:

Subspecialist ophthalmologists have usually completed training that allows them to work on eye conditions that are complex, involve a specific part of the eye, or affect certain groups of people. They also train more extensively than regular ophthalmologists to perform extremely intricate surgeries on delicate parts of the eye.

Ophthalmologists are responsible for the diagnosis, prevention, and treatment of almost all eye conditions and visual issues.

However, subspecialist ophthalmologists tend to treat and monitor certain conditions, such as:

Aside from caring for the eyes and vision, an ophthalmologists medical training may also equip them to notice symptoms of conditions that do not directly relate to the eye. In such cases, they can refer people for the appropriate treatment.

Many ophthalmologists also participate in some form of scientific research focusing on the causes of eye and vision conditions, as well as potential cures.

Most ophthalmologists are trained and certified to perform a wide range of medical and surgical procedures. The procedures that an ophthalmologist regularly carries out depend on several factors, such as the type of practice and specialty in which they work.

Some of the most common everyday procedures that an ophthalmologist will perform include diagnosing and monitoring mild eye and vision conditions. They will also spend time prescribing and fitting glasses and contact lenses to correct vision problems.

Subspecialist ophthalmologists tend to perform a smaller range of procedures on a day-to-day basis, focusing instead on the treatment of one condition or a few related conditions.

Procedures that subspecialists commonly perform include:

Most people see an ophthalmologist because they are experiencing chronic or severe vision symptoms or signs of eye conditions, such as:

A person may need emergency care from an ophthalmologist if their symptoms include:

A person may also receive a referral to an ophthalmologist if they have conditions or factors that can increase the risk of eye conditions, such as:

A family doctor, pediatrician, emergency room doctor, or optometrist usually refers a person to an ophthalmologist.

The American Academy of Ophthalmology recommend that people have a full medical eye exam by the age of 40 years so that an ophthalmologist can create a baseline profile of their eye health.

Having an eye health baseline is important because it makes it easier for doctors to spot or track eye or vision changes, which are often subtle and difficult to detect. Even healthy people can suddenly experience severe eye conditions.

Unlike ophthalmologists, optometrists and opticians are not medical doctors. However, members of all three distinct professions can, and frequently do, work in the same office or practice.

Optometrists are healthcare professionals who provide primary vision care. Optometrists hold a Doctor of Optometry (OD) degree, which requires the completion of 34 years of college and then 4 years of optometry school.

While the procedures that they perform vary between states and individual practices or clinics, most optometrists:

Opticians are a type of healthcare technician. They are specially trained to help design, confirm, select, or fit corrective vision devices, including contact lenses and eyeglass lenses and frames. Opticians cannot diagnose or treat conditions and must follow the prescription and guidance of optometrists and ophthalmologists.

The other eye healthcare professionals who frequently work with ophthalmologists and optometrists include:

Ophthalmologists are medical doctors who have undergone specialist training to diagnose and treat conditions involving the eyes and vision. They perform a wide range of medical and vision tests, minor office procedures, and some surgeries.

Some ophthalmologists specialize in a specific branch of ophthalmology that deals with particular procedures, parts of the eye, or groups of people.

A family doctor, pediatrician, or emergency room doctor usually refers a person to an ophthalmologist because of eye or vision problems. They refer people with symptoms and signs of conditions that need treating or monitoring.

Someone might also see an ophthalmologist if they have a higher risk of eye conditions or have health conditions that often lead to vision problems.

According to eye health authorities, most people should have an ophthalmologist perform a complete eye exam before the age of 40 years to establish a baseline profile of their eye health.

Link:
What is ophthalmology? Medical conditions, procedures, and more

Aesthetic Center

Experts treat patients who want to enhance their appearance through surgery. For example, treatment might involve eyelid reshaping, fat transfer or liposuction to alter a persons facial features. Patients who want aesthetic surgery receive care from specialists trained in both ophthalmic and plastic surgery.

UCLA Health ophthalmology conductsresearch in public health ophthalmology and provide high-impact, community-based services. For example, our Mobile Eye Clinic improves access to care in underserved communities.

Specialists use a team approach to research blinding diseases. Private donations, including an endowment established by the Ahmanson Foundation, fund this research center, established in 1997.

We provide core support for studies that include patient care. Every clinical trial and study involves vital, behind-the-scenes details that enable us to continue this research. At present, we are conducting almost 80 clinical research studies to help us better understand eye disorders and treatments.

Our ophthalmologists specialize in treating patients with diabetes-related eye conditions. Established more than a decade ago, the center has contributed significantly both to the understanding and the care of eye diseases in people with diabetes.

Specialists provide ultramodern vision correction treatments. We were one of a limited number of study sites in the United States that participated in the Food and Drug Administration (FDA) clinical trial of excimer laser technology. We also were the first site in Los Angeles to use FDA-approved laser treatment to correct myopia (nearsightedness) and astigmatism (imperfect eye curvature).

Our team offers high-quality care and rehabilitation and promotes collaborative research for macular degeneration (an eye disease that causes vision loss). Patients in this program, established in 1994, often have access to new treatments through clinical trials.

For more than 40 years, weve provided eye exams and screenings in neighborhoods where poverty and vision disabilities intersect. This 39-foot-long bus is outfitted with equipment for eye exams and supported by charitable donations. Each year, we provide eye care to more than 20,000 underserved adults and children in Southern California.

We established this center in 1985 to coordinate research, education and patient care of inflammatory eye disorders. Inflammatory diseases include those that cause eye swelling and destroy tissue. We have a long history of participating in clinical and drug therapy trials that advance our understanding of these diseases.

Specialists have renowned expertise in teaching, research and clinical management of tumors. Our program has achieved international recognition for the diagnosis and treatment of ocular melanoma (cancer of the eye).

We serve as a hub for national, long-term studies that investigate eye cancer. We also played an important role in the Collaborative Ocular Melanoma Study, a significant research initiative sponsored by the National Eye Institute.

Experts treat conditions that affect the optic nerve. Your optic nerves carry images from your eyes to your brain so you can see. If you have an optic nerve condition, your treatment might involve the expertise of ophthalmologists, orbital surgeons, neurologists, neuroradiologists or neurosurgeons.

We study and treat orbital (bony eye socket) diseases brought on by trauma, cancer, inflammation or infection. Our multidisciplinary collaboration offers patients a level of knowledge and expertise not found elsewhere in Southern California. We also have an active program in thyroid eye diseases, through which we study eye conditions that also affect your endocrine system.

We address the full spectrum of hereditary eye disorders (disorders you inherit from your parents). We offer diagnosis and treatment, as well as genetic counseling or DNA testing when appropriate.

Specialists in the Vision Genetics Center, established in 1978, collaborate with genetic research groups around the world. Our efforts ensure that patients have access to the most advanced treatments and clinical trials.

Our team provides rehabilitation services to help people with low vision maximize their function and improve their quality of life. We tailor the treatment plan to a patients individual goals and can help anyone who has difficulty with visual tasks, such as reading.

We also conduct research studies and pioneer novel ways to help people with vision loss. For example, we developed a system that uses rehabilitation delivered virtually to increase access to care. The approach involves video conferencing with a doctor. Now, we are part of a national, multicenter trial to evaluate how this new approach can improve reading ability.

Our specialists are experts in diagnosis, treatment and management of all conditions that affect the eyes, including pediatric vision concerns. Common conditions we treat include:

Astigmatism: An imperfect curving of your eye that causes blurry vision.

Blepharitis: Eyelid inflammation that can lead to dry eyes, redness or swelling.

Cataracts: When proteins build up in your eye and cause cloudy or fuzzy vision.

Conjunctivitis (pinkeye): Inflammation or infection in your eye that causes itching, redness and crusting around the eye.

Glaucoma: Conditions that damage your optic nerve (nerve that carries images to your brain), often caused by a buildup of pressure in your eye.

Macular degeneration: Deterioration of your retina (the back part of your eye that interprets and sends images to your brain).

Myopia (nearsightedness): A common vision condition in which you can focus on close objects but not on objects that are far away.

Our goal is to find the best, most effective treatment options for eye conditions. We provide a range of nonsurgical and surgical treatments.

Our specialists care for both routine and complex eye conditions. Nonsurgical treatments we offer include:

Anti-glare glasses: Devices designed to improve vision while reducing eye strain.

Artificial tears: Eyedrops that improve lubrication and moisture on your eyes surface.

Contact lenses: Thin devices placed directly over your eyes surface to improve vision.

Eye drops: Drops that contain saline and medication such as steroids or antihistamines.

Eye patches: A device made of cloth, plastic or an adhesive bandage that covers the eye.

Warm compresses for your eyes: Applying a clean, warm cloth over your eyes to relieve swelling, pain or inflammation.

We offer research-based, advanced surgical treatments for a range of eye conditions. Common surgeries include:

Blepharoplasty: Plastic surgery to change the appearance of your eyelids, often by correcting droopiness.

Corneal transplant: Repairing your cornea (transparent tissue that covers your eye) with donor tissue.

Orbital decompression: Removing fat or bone from behind the eye so that your eye sits back further in its socket.

Photodynamic therapy: Combining light energy with specific drugs to destroy precancerous or cancerous cells.

Pneumatic retinopexy: Injecting your eye with a small air bubble to push the retina in place while your surgeon repairs retinal tears.

Strabismus surgery: Surgically loosening or tightening eye muscles to correct irregular eye alignment (crossed eyes).

Vitrectomy: Removing fluid from the eye to treat problems with the retina or vitreous humor (the gel-like tissue that fills your eyeball).

The specialists on our ophthalmology team have led the way in the research and clinical care of eye conditions. We use the latest techniques and have pioneered advanced treatment options.

Call 310-825-5000 to request an appointment with an eye specialist at UCLA Health.

Original post:
Ophthalmology Services & Information | UCLA Health

Many people suffer from dry eye, when their eyes do not make enoughtears or the right quality of tears.Eye drops are often used to treat dry eye. However, some people find that having punctal plugs inserted into their eyes can help make them more comfortable.

Punctal plugs are tiny devices that are placed in the eyes tear ducts (called puncta). Puncta are the tiny openings that drain tears from your eyes. About the size of a grain of rice, the plug stops fluid from draining from the eye. This helps keep the eyes surface moist and comfortable, relieving itchy, burning and red eyes.

Punctal plugs are also called punctum plugs, lacrimal plugs or occluders. Usually they are inserted in the puncta of the upper or lower eyelids, or in both. Another type of plug is placed in a deeper part of the tear duct (the canaliculus).

These are made of a material (such as collagen) that gradually breaks down and is absorbed by the body. These plugs can last in the eye from a few days to months. Temporary plugs are often used to keep the eye moist after having refractive surgery, such as LASIK. They are also used when you want to try out punctal plugs to see if they help relieve your dry eye.

These are made of a longer-lasting medical plastic (such as silicone or acrylic). These plugs are designed to stay in the eye for years. They can be removed by your ophthalmologist if needed.

Another type of semi-permanent punctal plug is placed in a deeper part of the tear duct called the canaliculus. These plugs cannot be seen at all in the eye.

First your eye doctor will examine your eye to figure out the best type and size plug for your needs.

Your doctor may numb your tear ducts with anesthesia. In some cases, you may not need to have your eyes numbed. You may feel some pressure as the punctal plug is placed in your eyelid.

After the plugs are inserted, you are usually able to return to your normal activities right away.

As with any treatment or procedure, punctal plugs can have possible risks and side effects.

The most common side effect is having a scratchy orirritating feeling in the corner of your eye. Many people find this feeling goes away or they simply get used to it.

Other side effects and risks may include the following:

Most people find punctal plugs do not cause any problems. However, side effects can happen. If you feel any eye pain, scratchiness or if you think you have an eye infection, tell your eye doctor right away. They may choose to remove the plugs.

How the plugs are removed depends on which type you have. To remove silicon plugs, your eye doctor will use forceps to gently pull the plugs from the tear duct. Another way to remove these plugs is by flushing them out with a salt water solution. This method forces the plugs out of the tear ducts into the nose or throat.

Plugs that are deeper in the tear duct (in the canaliculus) are removed with surgery.

If artificial tears or other eye drops have not relieved your dry eye symptoms, talk with your ophthalmologist. They may recommend trying punctal plugs.

Go here to see the original:
Punctal Plugs - American Academy of Ophthalmology

Selection of lead candidate from initial short-list of 6 DMT-analogues

Lead candidate displays superior potency in two in vitro bioassays on two relevant human cell types

In vitro safety and biocompatibility testing using drug-loaded medical device demonstrates tolerability at doses anticipated to be within therapeutic range

Results to be leveraged by filing of Provisional Patent detailing a novel approach to treating primary open angle glaucoma

Initiates plans for second stage of R&D with Terasaki Institute for Biomedical Innovation

Toronto, Ontario--(Newsfile Corp. - May 3, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that in collaboration with the Terasaki Institute for Biomedical Innovation (TIBI), has selected its final lead drug candidate from a short list of six N,N-Dimethyltryptamine (DMT) analogue molecules. This decision, based on successful completion of the first phase of the sponsored research agreement, derives from the demonstration of lead candidate superiority as it relates to in vitro potency in two predictive bioassays, a favorable toxicity profile as well as physical, chemical, and metabolic properties necessary to fabricate a proprietary medical device capable of conveniently delivering sub-psychedelic levels of drug to the front of the eye over a sustained period.

With efforts related to discovery and candidate selection now complete, the Company intends to advance its program in primary open angle glaucoma (POAG) by entering into a second sponsored research collaboration with TIBI to undertake 1) mechanism of action studies, 2) optimize medical device drug release characteristics, 3) in vitro host-species justification studies to support, 4) evaluation of drug efficacy in an IND-enabling study of POAG with the goal of providing all necessary support to file an investigative new drug (IND) application with the United States Food and Drug Administration (the "FDA") to conduct clinical studies.

Paul Van Slyke, CSO of PharmaDrug, commented, "We are excited to announce that in collaboration with TIBI, we have successfully completed the studies necessary to elect the Company's lead drug candidate for the treatment of POAG. The next phase of this ongoing collaboration will start shortly and is underlined by the Company's strong commitment to work with outstanding research and development groups from around the world to provide innovative, life changing medications to patients at risk of vision loss as a consequence of insufficiently treated glaucoma."

Story continues

Under the terms of the first sponsored research agreement, PharmaDrug's DMT-analogue research program aimed to elect a drug development lead based on biological potency and toxicity and to use the development lead to engineer a medical device capable of sustained drug delivery to the front of the eye. The Company has now selected its lead candidate and completed fabrication and initial testing of its novel medical device designed to deliver therapeutic quantities of its DMT-analogues to the front of the eye. Specifically, drug-loaded medical device prototypes were suspended in a biological solution meant to mimic the somewhat harsh environment of the eye. Samples, maintained at body temperature were removed at defined periods of time over sixteen days and were quantified to determine concentration and rate of drug release and breakdown. Stability of the lead candidate molecule met necessary criteria set forth by the Company. The biocompatibility of drug-loaded medical device was examined by way of quantifying cell proliferation and live/dead staining on human ciliary muscle cells over time. Concentrations expected to be within the therapeutic range were found to not statistically impact cell viability the drug-loaded medical devices.

Most recently, potency of the lead candidate was evaluated in an in vitro cyclic adenosine 3':5' monophosphate (cAMP) production assay using human, primary trabecular meshwork (TM) cells and ciliary muscle (CM) cells. These cells, richly decorated with serotonin receptor 1a and 2a (5HT-1a, 5HT-2a), play a central role in the maintenance of healthy intraocular pressure. Tryptamine molecules, such as the Company's lead candidate are thought to bind to these receptors and elicit downstream biological outcomes which assist in the active drainage (reduction of pressure) of aqueous humor from the front of the eye to the posterior compartment. The Company's lead candidate demonstrated potent cAMP production following application, a statistically significant superiority compared to other candidate molecules examined (p<0001), and an unexpected bias towards cAMP production in TM cells versus CM cells.

Test article potency was previously evaluated using an in vitro calcium mobilization assay on TM and CM cells. Calcium mobilization is understood to provoke smooth muscle contraction, and specifically in the case of TM and CM cells, is thought to contribute to the maintenance of healthy IOP by channeling aqueous humor away from the front of the eye. The Company's lead candidate was found to activate calcium mobilization, to levels that were comparable or greater than the experimental positive control, ionomycin. The lead candidate was also examined for in vitro toxicity and found to be non-toxic to TM and CM cells at concentrations expected to be used in treatment for various eye diseases. Collectively results from the first phase of the sponsored research agreement will be used to draft an upcoming Provisional Patent application which describes use of tryptamine family members, fabricated into a proprietary medical device, to treat conditions marked by elevated intraocular pressure.

The Need for Improved Medications to Treat Primary Open Angle Glaucoma

Glaucoma is a disorder of the optic nerve that results in irreversible vision loss and is the second leading cause of blindness in the world, according to the World Health Organization. Glaucoma impacts more than 2.7 million people aged 40 or older in the United States and current treatments are known to have poor rates of compliance of up to 80% of patients. The global market for glaucoma was estimated by Market Scope at $4.8 billion in 2019 with the U.S. market representing $1.9 billion. Although the exact etiology of primary open angle glaucoma remains poorly understood, and may be variable across patient subsets, it is generally accepted that the observed increase in IOP correlates with progressive vision loss1. Current treatments for POAG primarily consist of eyedrops that can be grouped into three main categories: prostaglandin analogues, carbonic anhydrous inhibitors, and alpha-2 agonists. While these approaches usually provide partial improvement, they often result in side effects such as redness and stinging and require multiple daily applications; all of which diminish patient compliance. Tryptamines, including DMT-analogues are thought to work in a completely distinct way to lower IOP and as such potentially embody a new class of glaucoma medications that may be used alone, or in combination with already approved medications. The Company's streamlined focus on two highly promising, undisclosed tryptamines as a potential therapeutic solution in treating glaucoma represents a potential paradigm shift.

Modulating the serotonin receptor pathway to improve glaucoma outcomes

Key regions of the eye that regulate fluid dynamics, including maintenance of healthy IOP, are known to be richly decorated with various serotonin receptor family members. Previous research has highlighted the role of serotonin receptor signaling in the regulation of IOP2-5. Tryptamines, often hallucinogenic above certain threshold concentrations, constitute a large collection of molecules that selectively act on multiple different serotonin receptors including 5-HT1A and 5-HT2A. Topical application of several different tryptamines have shown early promise in preclinical models of elevated IOP, however formulation, delivery, the potential for undesirable hallucinogenic side effects, and the controlled substances act of 1970 have all contributed to a lack of development of tryptamines to treat this serious threat to vision.

About Terasaki Institute for Biomedical Innovation

The Terasaki Institute for Biomedical Innovation is a biotechnology institute which develops medical devices and cutting-edge protocols for a variety of diagnostic, monitoring and treatment applications. Their research platforms include work in biomaterials, cellular and tissue engineering, wearable biosensors and organs-on-a-chip, with specific expertise in novel polymer development.

About PharmaDrug Inc.

PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs. PharmaDrug owns 100% of Pharmadrug Production GmbH ("Pharmadrug Production"), a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the European Union. PharmaDrug owns 100% Sairiyo Therapeutics ("Sairiyo"), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Company also owns 100% of Super Smart, a company building a vertically integrated retail business with the goal to elevate the use of functional mushrooms, and psilocybin mushrooms where federally legal, as natural based medicines.

For further information, please contact:

Daniel Cohen, Chairman and CEO dcohen@pharmadrug.co(647) 202-1824

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This press release contains "forward-looking information" within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. Generally, forward-looking information may be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "proposed", "is expected", "budgets", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. In particular, this press release contains forward-looking information in relation to: future in vivo efficacy testing in an accepted model of primary open angle glaucoma (POAG), the ability to complete the required studies and obtain regulatory approval, and the impact the Company's potential products will have on treating glaucoma. This forward-looking information reflects the Company's current beliefs and is based on information currently available to the Company and on assumptions the Company believes are reasonable. These assumptions include, but are not limited to the ability of the Company to successfully execute on its plans for the Company and its affiliated entities; the ability to obtain required regulatory approvals and the Company's continued response and ability to navigate the COVID-19 pandemic being consistent with, or better than, its ability and response to date.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; the actual results of the Company's future operations; competition; changes in legislation affecting the Company; the ability to obtain and maintain required permits and approvals, the timing and availability of external financing on acceptable terms; lack of qualified, skilled labour or loss of key individuals; risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions; and a deterioration of financial markets that could limit the Company's ability to obtain external financing.

A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR website at http://www.sedar.com. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

Forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, are subject to change after such date. However, the Company expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

References:

Weinreb RN, Leung CK, Crowston JG, Medeiros FA, Friedman DS, Wiggs JL, Martin KR. Primary open-angle glaucoma. Nat Rev Dis Primers. 2016 Sep 22;2:16067. doi: 10.1038/nrdp.2016.67. PMID: 27654570.

May JA, McLaughlin MA, Sharif NA, Hellberg MR, Dean TR. Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J Pharmacol Exp Ther. 2003 Jul;306(1):301-9. doi: 10.1124/jpet.103.049528. Epub 2003 Apr 3. PMID: 12676887.

Sharif NA. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. Curr Drug Targets. 2010 Aug;11(8):978-93. doi: 10.2174/138945010791591278. PMID: 20426763.

Najam A Sharif & Jesse A May (2011) Potential for serotonergic agents to treat elevated intraocular pressure and glaucoma: focus on 5-HT2 receptor agonists, Expert Review of Ophthalmology, 6:1, 105-120, DOI: 10.1586/eop.10.69

Sharif NA, McLaughlin MA, Kelly CR. AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist. J Ocul Pharmacol Ther. 2007 Feb;23(1):1-13. doi: 10.1089/jop.2006.0093. PMID: 17341144.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/122498

See the original post:
Pharmadrug Advances Opthalmology Program with Final Selection of Lead DMT-Analogue to Provide Sustained Control of Elevated Intraocular Pressure for...

There has been a significant increase in eye diseases in the people of India for the last several years. The doctors of The Retina Centre, Guwahati told the media on this subject that there can be many reasons for eye problems, including pollution, excessive use of mobile Use, stress, use of tobacco and other intoxicants, disordered eating, eye injury etc. are prominent.

Our eyes are precious but our slightest carelessness towards the eyes can also make us a victim of blindness. Many people ignore the initial symptoms of eye problems and gradually these problems take a serious form in them. That is why it is necessary not to ignore eye diseases and consult a doctor immediately as soon as the initial symptoms appear.

The officials of The Retina Center told the media that this institute of theirs has become the best eye hospital in the entire North-East region. Officials said that not only are the best doctors working here, but advanced medical procedures are available at affordable rates through modern resources.

The following eye diseases are treated by The Retina Centre.

Retinal Diseases:

The retina is the tissue that lines the inside of the eye and is sensitive to light. It sends visual messages to the brain through the optic nerve. Retinal diseases can affect any part of the retina and vary widely, but most of them cause visual symptoms. In the hospital, scleral buckling, vitrectomy (without suture), pneumorretinopexy, anti VEGF treatment, laser treatment etc. are done.

Corneal Disorders:

The cornea is a clear layer in front of the iris and the pupil. It protects the iris and lens and helps to focus light on the retina. Corneal disease is a serious condition that can lead to deformity, scarring and eventually blindness. Keratoplasty andTreatment services like Keratoprosthesis are available.

cataracts :

Cataract is a serious disease of the eyes. Cataracts usually occur with ageing or develop for no apparent reason. Most cataracts can be removed and replaced with artificial lenses. For this, facilities like Phacoemulsification with IOL implantation are available in the hospital.

Glaucoma:

Glaucoma is progressive optic nerve damage that leads to irreversible loss of vision. Glaucoma can occur at any age but it is 6 times more common in people over the age of 60. The Retina Center provides treatment for this like Filtration Surgery, Valve Implantation.

eye surgery:

Eye surgery Early diagnosis of eye conditions can help prevent further deterioration in eye health, improve vision and cure most eye diseases. Treatment includes simple medication, non-invasive and invasive procedures may be involved. For this, facilities like Retina Surgery, Glaucoma, Cataract Surgery, Neuro Opthalmology, Squint, Oculoplasty, Pediatric, Opthalmology are available in the hospital.

Hospital Address and Contact:

5th and 6th Floor, Subham Bijay Crescent,

6th Mile, Rukmini Gaon,

GS Road, Guwahati-781022, Assam

http://www.theretinacentre.com

Go here to read the rest:
Best Eye Hospital in North-East Region : The Retina Centre, Guwahati - APN News

Led by Ukrainian doctor practicing in the UK, Dr Sergey Tadtayev a consultant urologist surgeon, staff at Chiltern in Great Missenden, and Shelburne Hospital have managed to deliver supplies to the war-torn country.

Circle Health Group, Sergeys hospital operator, has also played a key role in getting the urgent supplies to Ukraine.

In response to direct requests from Ukrainian doctors, the hospitals have worked with the Ukrainian doctors union (Ukraine Medical Association) and the British Red Cross to identify needs in war-hit hospitals.

Also, Sergey has galvanised his Circle colleagues to gather 10-truck loads including 200 pallets of vital kit and medical supplies from across the groups national network of 53 hospitals.

Sergey said: My heart breaks for my fellow doctors back home who are fighting heroically to care for the sick and wounded even as the bombs continue to fall.

"Hospitals are struggling to get basic supplies because transport and manufacturing have been so badly disrupted, so I knew I had to do something to help.

Moving 100+ tonnes of medical supplies between hospitals separated by thousands of miles and several borders has been an incredible team effort, and I have been overwhelmed by the generosity of my colleagues at Circle Health Group.

"They are moving heaven and earth to get help to those who really need it on the frontline, and I am humbled by the solidarity and support for my homeland.

Ventilators, crutches, walking frames, respiratory masks, scrubs, bandages, wound kits, operating tables and other medical supplies have been stock-piled from Circle hospitals across the country and delivered directly to the doors of five hospitals covering North, South, East and West Ukraine.

Upon receipt of the urgent supplies, the hospitals distribute a portion to local community hospitals.

A team of volunteers from the UK, Poland and Ukraine have made the journey on a weekly basis since 15 March to deliver urgent supplies, navigating their way through war-torn regions and areas of conflict to reach the hospitals in Kyiv, Kharkiv, Mykolaiv, Odessa and Lviv.

Circle Health Group has committed to continue the weekly delivery programme for as long as the supplies are required.

The latest delivery, which departed the UK on Wednesday 13 April and arrived at a Kharkiv hospitals on Easter Sunday (17 April), contained 185,500 of medical equipment loaded on 35 pallets, including five ventilators, an operating table, patient monitors, suction tubing and chest drainage sets and sterile gowns.

One of the hospitals opthalmic consultants, Mandeep Bindra, and Healthcare Assistant Adinda Ecott, co-ordinated the collection of supplies ranging from blankets to hot water bottles and baby food. Mandeep personally drove the supplies to two collection centres, one in Hounslow and one at the Olympic Lodge in Aylesbury.

The collected items will then be transported by lorry to the Polish border where they will be given to Ukrainian families.

Overall, 1.4 million worth of supplies have been sent from Circle Health Group hospitals.

Paolo Pieri, CEO of Circle Health Group, said: Were so grateful to the hundreds of people across the country who have contributed to this effort, from staff to partners and suppliers, and the brave drivers who have put themselves at considerable personal risk."

Read the rest here:
Bucks hospitals rally to deliver urgent supplies to Ukraine - Bucks Herald

Equities analysts expect LianBio (NASDAQ:LIAN Get Rating) to announce earnings per share (EPS) of ($0.26) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for LianBios earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.31). The firm is expected to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that LianBio will report full-year earnings of ($1.32) per share for the current fiscal year, with EPS estimates ranging from ($1.65) to ($1.07). For the next year, analysts expect that the business will report earnings of ($1.73) per share, with EPS estimates ranging from ($2.20) to ($1.44). Zacks Investment Researchs EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for LianBio.

LianBio (NASDAQ:LIAN Get Rating) last posted its earnings results on Wednesday, March 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts consensus estimates of ($0.72) by $0.44.

Several institutional investors have recently modified their holdings of LIAN. Victory Capital Management Inc. acquired a new stake in LianBio during the 4th quarter worth $1,069,000. Bank of America Corp DE acquired a new stake in LianBio during the 4th quarter worth $519,000. Alps Advisors Inc. acquired a new stake in LianBio during the 4th quarter worth $750,000. Element Capital Management LLC acquired a new stake in LianBio during the 4th quarter worth $124,000. Finally, TD Asset Management Inc. acquired a new position in shares of LianBio in the 4th quarter valued at $954,000. 62.99% of the stock is owned by institutional investors and hedge funds.

Shares of LianBio stock traded down $0.26 during midday trading on Thursday, reaching $4.91. The company had a trading volume of 435,320 shares, compared to its average volume of 411,834. The companys fifty day moving average is $4.19. LianBio has a 1-year low of $2.61 and a 1-year high of $16.37.

About LianBio (Get Rating)

Lianbio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor IO combinations; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric and other cancers; BBP-398 for solid tumors; Omilancor for ulcerative and Crohn's disease; NH-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.

Recommended Stories

Get a free copy of the Zacks research report on LianBio (LIAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with MarketBeat.com's FREE daily email newsletter.

See more here:
LianBio (NASDAQ:LIAN) Expected to Post Earnings of -$0.26 Per Share - Defense World

With the number of patients getting physically examined at outpatient departments (OPDs) of Post Graduate Institute of Medical Education and Research (PGIMER) rising by 67% over a week, the institute will call a review meeting in a week to decide upon the operations.

The PGIMER had resumed the walk-in facility for physical consultation at its OPDs on September 27. Since then, in the six working days, 32,913 patients were physically examined while 8,540 people were given consultation on telephones. The OPDs were closed on Saturday (Gandhi Jayanti) and Sunday.

On Monday, 6,579 patients got physical consultation at the hospitals New OPD department, as compared to 3,942 last Monday. Before the resumption of the walk-in facility, nearly 3,000 patients were visiting various OPDs daily, after prior appointments through tele-consultation or official website.

Keeping in view the possibility of a third wave, the institute authorities believe that capping the number of patients for physical examination is important. The institute is providing tele-consultation only between 8 am to 9 am, to scale up physical consultation.

The number of patients coming to the institute is more than expected. Since Covid-19 cases in Chandigarh and neighbouring states are fluctuating daily, crowding at one place can spread the infection. A cap of numbers and resuming OPDs in a phased manner is a must, said a PGIMER official, who did not wish to be named.

Dr Jagat Ram, director, PGIMER, said that on an average, 6,000 patients are visiting the institute daily, and each patient has two or three attendants with them. The total footfall is more than 18,000 daily.

At present, we are trying to manage the crowd and are accessing problems being faced by patients. In a week, we will call a review meeting with heads of each department and will decide upon further action. Guidelines on OPD operations will be reviewed, he said.

Before the contagion, over 10,000 patients visited PGIMERs OPDs daily. Since the suspension of walk-in consultation and online appointments in March last year, the institute had been providing OPD services through tele-consultation. From June 21 this year, physical consultations resumed, but only after prior appointment through tele-consultation.

On September 6, the institute also restarted an online appointment facility, but with a cap of 30 patients per department to ensure adherence to Covid protocols. Later, the limit was increased to 50 patients, with 100 allowed at three major departments opthalmology (eye), hepatology (liver) and internal medicine.

Now, patients can simply walk into the institutes New OPD between 9.15am and 11am and get registered.

More:
PGIMER to review operations as OPD footfall rises - Hindustan Times

Newly Report on Opthalmology Drugs and Devices Market 2021, Growth, Share Types and Key Players | Merck (US), Pfizer (US), Roche Holdings (Switzerland), Santen Pharmaceutical(Japan), Abbott Medical Optics (US), Alcon (Switzerland), Bausch& Lomb (US), Carl Zeiss Meditec (Germany), Essilor International S.A. (France), Johnson& Johnson (US), Nidek(Japan), Topcon Corporation (Japan)

COVID-19 Impact on Global Opthalmology Drugs and Devices Market Research Report 2021-2028

The global Opthalmology Drugs and Devices market report examines the market position and viewpoint of the market worldwide, from various angles, such as from the key players point, geological regions, types of product and application. This Opthalmology Drugs and Devices report highlights the key driving factors, constraint, opportunities, challenges in the competitive market. It also offers thorough Opthalmology Drugs and Devices analysis on the market stake, classification, and revenue projection. The Opthalmology Drugs and Devices market report delivers market status from the readers point of view, providing certain market stats and business intuitions. The global Opthalmology Drugs and Devices industry includes historical and futuristic data related to the industry. It also includes company information of each market player, capacity, profit, Opthalmology Drugs and Devices product information, price, and so on.

The latest Opthalmology Drugs and Devices market report published by Cognitive Market Research offers a competency-based analysis and global market estimate, developed using evaluable methods, to provide a clear view of current and expected growth patterns. The report also contains market analysis by geographic location across the globe as well as major markets.

The key manufacturers covered in this report areMerck (US), Pfizer (US), Roche Holdings (Switzerland), Santen Pharmaceutical(Japan), Abbott Medical Optics (US), Alcon (Switzerland), Bausch& Lomb (US), Carl Zeiss Meditec (Germany), Essilor International S.A. (France), Johnson& Johnson (US), Nidek(Japan), Topcon Corporation (Japan)

The product type segment discusses the different kinds of products made available by the Global Opthalmology Drugs and Devices market:Device, Drug

The product application segment examines the different end-users operational in the Global {Opthalmology Drugs and Devices} market:Hosptial, Clinic, Others

Get a sample copy of the report @ https://cognitivemarketresearch.com/medical-devicesconsumables/opthalmology-drugs-and-devices-market-report#download_report

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Research MethodologyThe data that has been collected is from a multitude of different services that include both primary and secondary sources. The data also includes a list of the different factors that affect the Opthalmology Drugs and Devices market either positively or negatively. The data has been subjected to a SWOT analysis that can be used to accurately predict the various parameters that are used to measure a companys growth. The strengths along with various weaknesses faced by a company are included in the report along with a comprehensive analysis of the different threats and opportunities that can be exploited.

Get Enquiry on this Report @ https://cognitivemarketresearch.com/medical-devicesconsumables/opthalmology-drugs-and-devices-market-report#download_report

To understand the global Opthalmology Drugs and Devices market dynamics, the market is analyzed across major global regions and countries. Cognitive Market Research provides customized specific regional and country-wise analysis of the key geographical regions as follows:North AmericaEuropeAsia Pacific CounterMiddle East & AfricaLatin AmericaAmerica Country (United States, Canada)South AmericaAsia Country (China, Japan, India, Korea)Europe Country (Germany, UK, France, Italy)Other Country (Middle East, Africa, GCC)

About Author:Cognitive Market Research is the new buzzword in the market, which helps in understanding the market potential of any product in the market. This helps in understanding the market players and the growth forecast of the products and so the company. This is where market research companies come into the picture. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world.

Contact Us:Cognitive Market ResearchContact Person: Nicolas Shaw, Sales ManagerEmail: [emailprotected]Phone: +1 312-376-8303 | (+44) 20-8144-9523

https://murphyshockeylaw.net/

Read the rest here:
Coronavirus Impact Editon of Opthalmology Drugs and Devices Coronavirus Impact Editon of Insights with COVID-19 Impact Analysis by 2020Merck (US),...

This Tissue Ablation market report depicts industrial analysis, growth factors, driving factors and recent market trends, which greatly benefit to the newly entering key players in the industry. This market report is very important for them as it covers all the profit making related factors that play a major role in driving the growth of the market. These factors include technological progressions, confronts, opportunities for the players and modern inclinations. One can get a detailed review of the market and also a brief insight of the market evolution. All this information is provided in the form of an overview on the current market trends and upcoming projections. This research analysis further proceeds with growth aspects, volume of the industry and market share.

Get the complete sample, please click:https://www.globalmarketmonitor.com/request.php?type=1&rid=726930

For the better understanding of the market, considering market experts opinions is very important. This Tissue Ablation market report discusses the expert opinions in detail. Additionally, it also consists of type wise and application wise sections. Every type describes about the production for the forecast period 2021 to 2027. Every section understanding greatly aids to recognize the significance of elements that work effectively in market growth. This market report sheds light on key players of the market to know about the strategies they are following in the market which include new product launchings, collaborations, acquisitions and mergers.

Major Manufacture:St. Jude Medical Boston Scientific Johnson & Johnson Medtronic

20% Discount is available on Tissue Ablation market report:https://www.globalmarketmonitor.com/request.php?type=3&rid=726930

Market Segments by Application:Oncology Cardiology Gynecology Cosmetology Urology Opthalmology

Worldwide Tissue Ablation Market by Type:Radiofrequency Ablation Ultrasound Ablation Laser-Based Ablation Irreversible Electroporation Cryoablation Devices Microwaves Ablation Hydrothermal Ablation External Beam Radiation Therapy (EBRT)

Table of Content1 Report Overview1.1 Product Definition and Scope1.2 PEST (Political, Economic, Social and Technological) Analysis of Tissue Ablation Market2 Market Trends and Competitive Landscape3 Segmentation of Tissue Ablation Market by Types4 Segmentation of Tissue Ablation Market by End-Users5 Market Analysis by Major Regions6 Product Commodity of Tissue Ablation Market in Major Countries7 North America Tissue Ablation Landscape Analysis8 Europe Tissue Ablation Landscape Analysis9 Asia Pacific Tissue Ablation Landscape Analysis10 Latin America, Middle East & Africa Tissue Ablation Landscape Analysis 11 Major Players Profile

This Tissue Ablation market report also includes specific sections by application and type. These market variables include, for example, the evolving needs of clients in diverse regions such as East Asia, North America, Latin America, and the Middle East and Africa, among others. The classification to drivers is depicted by a systematic evaluation of the controls, which also allows for key arranging. In addition, insights into the opinions of market experts have been used to gain a better picture of the overall market. To examine critical information and insight from the partnerships with a specific purpose in mind, equipment and programming exploration arrangements are used. This specific Tissue Ablation market report, also known as the global report, includes a broad analysis of the market in several regions of North America, Latin America, Asia Pacific, the Middle East & Africa, and Europe. The study includes details such as current market trends, past performance, and future prospects. Its an inside and out report in this sense.

Tissue Ablation Market Intended Audience: Tissue Ablation manufacturers Tissue Ablation traders, distributors, and suppliers Tissue Ablation industry associations Product managers, Tissue Ablation industry administrator, C-level executives of the industries Market Research and consulting firms

The significant findings mentioned in this global Tissue Ablation market research analysis are obtained from different trustworthy sources. Every minute detail about market scenario and business strategies are provided in this market report. With the help of significant data provided in this market report is greatly help new entrants to get overall idea about market strategies. Market data provided here is of great use as it forecasts future productivity and helps in business related decision making. This comprehensive Tissue Ablation market analysis gives precise data about market constraints, segment analysis, region wise market size, competitive landscape and growth factors. It also forecasts the global market scenario for the period 2021-2027.

Related Market Research Reports:9-Decanoic Acid Methyl Ester Market Reporthttps://www.globalmarketmonitor.com/reports/605488-9-decanoic-acid-methyl-ester-market-report.html

Menopausal Hot Flashes Drugs Market Reporthttps://www.globalmarketmonitor.com/reports/580817-menopausal-hot-flashes-drugs-market-report.html

Pharmaceutical Excipients Market Reporthttps://www.globalmarketmonitor.com/reports/585691-pharmaceutical-excipients-market-report.html

Protein Sequencer Market Reporthttps://www.globalmarketmonitor.com/reports/743817-protein-sequencer-market-report.html

Spring Balances Market Reporthttps://www.globalmarketmonitor.com/reports/675536-spring-balances-market-report.html

Vitamin B6 (Pyridoxine Hydrochloride) Market Reporthttps://www.globalmarketmonitor.com/reports/609463-vitamin-b6pyridoxine-hydrochloridemarket-report.html

Visit link:
Tissue Ablation Market Value Projected to Expand by 2027 26 Sports - 2x6 Sports

Opthalmology Pacs Market Scenario 2021: Latest AnalysisThis detailed market study covers Opthalmology Pacs Market growth potentials which can assist the stakeholders to understand key trends and prospects in the Opthalmology Pacs market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources and is analyzed using various tools. It helps to gain insights into the markets growth potential, which can help investors identify scope and opportunities. The analysis also provides details of each segment in the global Opthalmology Pacs market

Get PDF Sample Report of Opthalmology Pacs (COVID-19 Version) Market 2021, Click Here @ https://www.adroitmarketresearch.com/contacts/request-sample/608?utm_source=Pa

The current trends in the Opthalmology Pacs market combined with a variety of growth opportunities, key drivers, restraints, challenges, and other critical aspects have been clearly set out in the Opthalmology Pacs market report. Additionally, the report takes into account various market dynamics, which in turn creates a variety of development prospects for the major players in the Opthalmology Pacs industry.

The global Opthalmology Pacs market is illustrated by key results:1.The overview, scope, definition and the factors driving or impaling the market discussed strategically.2.Opthalmology Pacs full analysis, DROCs analysis, Competitor analysis with the key players introduction and revenue generated.3.Segments and Sub-segments full analysis with correct market estimations that will help diversify the market with ease.4.Global Opthalmology Pacs market report advices on the report values and the details that are focused to grow in the industry and reviews the challenges faced in the market during the pandemic.

Some of the Important and Key Players of the Global Opthalmology Pacs Market:

Topcon Corporation, IBM corporation, Carl Zeiss Meditec AG, EyePACS, Heidelberg Engineering and more.

Browse the complete report Along with TOC @ https://www.adroitmarketresearch.com/industry-reports/opthalmology-pacs-market?utm_source=Pa

Detailed SWOT analysis of these players has also been included in the Opthalmology Pacs market report to determine the threats and opportunities faced by them while operating in the Opthalmology Pacs industry. The Opthalmology Pacs market 2021 industry research study further analyzes the global Opthalmology Pacs industry in terms of revenue and has presented the historical data and forecast figures with the help of tables, charts, and infographics. The Opthalmology Pacs report also provides a comprehensive analysis of the global Opthalmology Pacs market with the help of several analytical tools and helps in determining the growth prospects and opportunities of the Opthalmology Pacs industry. It also helps in understanding the major factors that affect the structure and profitability of the global Opthalmology Pacs industry.

Opthalmology Pacs Market SegmentationType Analysis of Opthalmology Pacs Market:

By End-Use, market is segmented into:

HospitalsAmbulatory Surgical Center (ASCS) & Specialty ClinicsOthersBy Type, market is segmented into:

Standalone PACSIntegrated PACSBy Delivery Model, market is segmented into:

Cloud/ web based modelsOn-premise modelsOthers

Table of Contents1.Opthalmology Pacs Market Overview: Market Segment, Market Size, Sales and Growth, Price by Type2.Global Opthalmology Pacs Market Competition by Company/Manufacturers: Market Share, Price, Base Distribution, Sales Area, Product by Company and Opthalmology Pacs Market Competitive Situation and Trends, Opthalmology Pacs Market Share of Top 5 and Top 10 Players3.Opthalmology Pacs Company Profiles and Sales Data: Company/Manufacturers Basic Information, Manufacturing Base and Competitors, Opthalmology Pacs Product Category, Application and Specification, Opthalmology Pacs Manufacturers Sales, Revenue, Price and Gross Margin(2018-2021) and Main Business Overview4.Opthalmology Pacs Market Status and Outlook by Regions (North America, Europe, Asia-Pacific, South America, Middle East, and Africa): Market Size and CAGR, Sales and Revenue, Sales Market Share by Regions5.Opthalmology Pacs Application: Opthalmology Pacs Product Segment, Sales and Market Share by Application6.Global Opthalmology Pacs Market Forecast: Sales, Revenue, Growth Rate Forecast (2021-2027) and Forecast by Regions, by Type, by Application7.Opthalmology Pacs Upstream Raw Materials8.Marketing Strategy Analysis, Distributors9.Research Findings and Conclusion10.Methodology/Research Approach

If you have any questions on this report, please reach out to us @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/608?utm_source=Pa

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more:
Opthalmology Pacs Market Size, Share Global Industry Current Trends, Top Companies, Application, Growth Factors, Development and Forecast to 2026...

Request Download Sample Ask For Discount Company Profile

New Jersey, United States,- Verified Market Reports has recently published a market research report titled, Connective Tissue Growth Factor Market Size, Status and Forecast 2021-2027. Analysts have used primary and secondary research methodologies to determine the path of the market. The data includes historic and forecast values for a well-rounded understanding. It is a phenomenal compilation of important studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the Connective Tissue Growth Factor market. Players can use the accurate market facts and figures and statistical studies provided in the report to understand the current and future growth of the Connective Tissue Growth Factor market.

This report includes the assessment of various drivers, government policies, technological innovations, upcoming technologies, opportunities, market risks, restraints, market barriers, challenges, trends, competitive landscape, and segments which gives an exact picture of the growth of the Connective Tissue Growth Factor market.

Competitive analysis:

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides an in-depth analysis of the competition in the Connective Tissue Growth Factor market.

The report covers the following key players in the Connective Tissue Growth Factor Market:

Segmentation of Connective Tissue Growth Factor Market:

The Connective Tissue Growth Factor market report has been segmented into Types, Applications, and End-users. It provides the market share of each segment participating in the Connective Tissue Growth Factor market. Companies operating in this market have a thorough understanding of the fastest-growing segment. That way, they can identify their target customers and allocate their resources wisely. Segment analysis helps create the perfect environment for engagement, customer loyalty, and acquisition. This section will help companies operating in the Connective Tissue Growth Factor market identify key areas of intervention while making their strategic investments.

By the product type, the market is primarily split into:

BLR-200 IB-DMD OLX-201 PBI-4050s Hypertrophic Scars Opthalmology Genetic Disorders Liver Fibrosiss Regional and Country-level Analysis The Connective Tis

By the application, this report covers the following segments:

BLR-200 IB-DMD OLX-201 PBI-4050s Segment by Application the Connective Tissue Growth Factor market is segmented into Hypertrophic Scars Opthalmology Genetic Disorders

Connective Tissue Growth Factor Market Report Scope

Regional analysis:

The Connective Tissue Growth Factor market report covers the analysis of various regions such as North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Market trends change by region and result in changes due to their physical environment. The report, therefore, covers key regions with sales, revenue, market share and growth rate of Connective Tissue Growth Factor in these regions from 2020 to 2027. It analyzes the region with the highest market share as well as the fastest growing region of the Connective Tissue Growth Factor market. The report by region is then broken down into analyzes at the country level. For example, North America is divided into the United States and Canada. Europe includes the UK, France, and Germany, followed by APAC, which includes countries like China, India, and Japan. Latin America is made up of countries like Mexico and Brazil, and the MEA countries included in the Connective Tissue Growth Factor market are the GCC countries and South Africa.

Research methodology:

The research methodology used to aggregate the Connective Tissue Growth Factor market report involves a combination of primary and secondary research approaches. The research team starts desk research from various sources to collect data on the Connective Tissue Growth Factor market. The report combined its data from reliable secondary sources such as company annual reports, industry publications, news, government websites and more. In addition, the primary research includes interviews to get first-hand market intelligence. Our analysts interviewed several C-level executives, decision-makers, board members, key opinion leaders, industry veterans and other stakeholders in the Connective Tissue Growth Factor market. All of the data is then combined and presented in a report to enable a deep understanding and analysis of the Connective Tissue Growth Factor market.

Why buy Connective Tissue Growth Factor Market Report?

The Connective Tissue Growth Factor market report provides a comprehensive overview of the current market and forecast till 2020-2027. It helps to identify the opportunities associated with the market in the near future. This gives our users a clear idea of ??where to use their resources. The report also includes industry dynamics such as drivers, restraints, and market opportunities that are significantly influencing the growth of the Connective Tissue Growth Factor market. In-depth study of general market expansion that helps users make product launch and asset development decisions. The report covers recent developments and changing market trends with the aim of making the appropriate decisions.

Visualize Connective Tissue Growth Factor Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment and Key players of your market. Present your Market Report & findings with inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us: Verified Market Reports

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information enriched research studies.

We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyse data on more than 25,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Our research spans over a multitude of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages etc. Having serviced many Fortune 2000 organizations, we bring a rich and reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: [emailprotected]

Website: https://www.verifiedmarketreports.com/

Link:
Connective Tissue Growth Factor Market Size | Latest COVID19 Impact Analysis | Demand, Growth, Trends, Segmentation and Forecasts to 2027 -...

In the field of medical science, lasers are used in specific wavelengths of light, from red to near infrared, in order to create beneficial and therapeutic effects. Such kind of results include improved time of healing, reduction in pain, increased blood circulation and a reduction in swelling. A trend in the laser therapy devices market includes a shift towards pain-free and non-invasive procedures. The procedures related to medical aesthetics, both invasive and non-invasive, are becoming increasingly popular amongst the younger population. These procedures using lasers have replaced the traditional surgery and they give superior results with minimum complications. Moreover, non-invasive laser procedures like removal of scars, resurfacing of the skin, facelifts, laser hair removal and liposuction are becoming increasingly popular as they promote a younger looking appearance with minimal side effects.

Global Market Research Report Overview on Laser Therapy Devices @https://www.futuremarketinsights.com/reports/laser-therapy-devices-market

The global laser therapy devices market is slated to touch a value of about US$ 1,900 Mn in the year 2022 and display a moderate CAGR during the assessment period.

4 Forecast Highlights on Global Laser therapy devices Market

As per the forecast of Future Market Insights, the gas laser segment is slated to touch a value of more than US$ 470 Mn in the year 2022. This represents a robust CAGR during the assessment period of 2017-2022. The gas laser segment is estimated to account for nearly one-fourth of the revenue share of the device type segment by the year 2017 and is forecasted to gain market share by 2022 over 2017.

As per the forecast of Future Market Insights, the specialized clinics segment will reach a value of about US$ 825 Mn in the year 2017. This represents a moderate CAGR growth during the forecast period. The specialized clinics segment is forecasted to account for more than half of the total revenue share of the end user segment by the end of the year 2017 and is expected to gain in market share by 2022 as compared with the year 2017.

As per the forecast of Future Market Insights, the ophthalmology segment is slated to reach a value of more than US$ 560 Mn in 2022. The ophthalmology segment is expected to gain market share by the end of the year 2022. The largest share is contributed by the North America region in the ophthalmology segment.

A Sample of this report is available upon request@https://www.futuremarketinsights.com/reports/sample/rep-gb-5241

Future Market Insights forecasts the United States laser therapy devices market to exhibit a compound annual growth rate (CAGR) of more than 4% from 2017 to 2022.

The report has also included the profiles of some of the leading companies in the laser therapy devices market like Thermo Fisher Scientific, Inc., Lumenis Ltd., Boston Scientific Corporation, Danaher Corporation, IPG Photonics Corporation, Alma Lasers, Ltd., Coherent, Inc., Fotona d.d., Biolitec AG and Hologic Inc.

1. Global Laser Therapy Devices Market Executive Summary

2. Global Laser Therapy Devices Market Overview

2.1. Introduction

2.1.1. Global Laser Therapy Devices Market Taxonomy

2.1.2. Global Laser Therapy Devices Market Definition

2.2. Global Laser Therapy Devices Market Size (US$ Mn) and Forecast, 2012-2022

2.2.1. Global Laser Therapy Devices Market Y-o-Y Growth

2.3. Global Laser Therapy Devices Market Dynamics

View Report Table of Contents, Figures, and Tables@https://www.futuremarketinsights.com/reports/laser-therapy-devices-market/toc

2.4. Supply Chain

2.5. Cost Structure

2.6. Regulations

2.7. Procedure Numbers By Region

2.8. Pricing Analysis

2.9. Key Participants Market Presence (Intensity Map) By Region

3. Global Laser Therapy Devices Market Analysis and Forecast By Device Type

3.1. Global Laser Therapy Devices Market Size and Forecast By Device Type, 2012-2022

3.1.1. Solid-state Laser Market Size and Forecast, 2012-2022

3.1.1.1. Revenue (US$ Mn) Comparison, By Region

3.1.1.2. Market Share Comparison, By Region

3.1.1.3. Y-o-Y growth Comparison, By Region

3.1.2. Gas Laser Market Size and Forecast, 2012-2022

3.1.2.1. Revenue (US$ Mn) Comparison, By Region

3.1.2.2. Market Share Comparison, By Region

3.1.2.3. Y-o-Y growth Comparison, By Region

3.1.3. Liquid Laser Market Size and Forecast, 2012-2022

3.1.3.1. Revenue (US$ Mn) Comparison, By Region

3.1.3.2. Market Share Comparison, By Region

3.1.3.3. Y-o-Y growth Comparison, By Region

3.1.4. Semiconductor Laser Market Size and Forecast, 2012-2022

3.1.4.1. Revenue (US$ Mn) Comparison, By Region

3.1.4.2. Market Share Comparison, By Region

3.1.4.3. Y-o-Y growth Comparison, By Region

4. Global Laser Therapy Devices Market Analysis and Forecast By End User

4.1. Global Laser Therapy Devices Market Size and Forecast By End User, 2012-2022

4.1.1. Hospitals Market Size and Forecast, 2012-2022

4.1.1.1. Revenue (US$ Mn) Comparison, By Region

4.1.1.2. Market Share Comparison, By Region

4.1.1.3. Y-o-Y growth Comparison, By Region

4.1.2. Specialized Clinics Market Size and Forecast, 2012-2022

4.1.2.1. Revenue (US$ Mn) Comparison, By Region

4.1.2.2. Market Share Comparison, By Region

4.1.2.3. Y-o-Y growth Comparison, By Region

4.1.3. Ambulatory Surgical Centers Market Size and Forecast, 2012-2022

4.1.3.1. Revenue (US$ Mn) Comparison, By Region

4.1.3.2. Market Share Comparison, By Region

4.1.3.3. Y-o-Y growth Comparison, By Region

4.1.4. Other End users Market Size and Forecast, 2012-2022

4.1.4.1. Revenue (US$ Mn) Comparison, By Region

4.1.4.2. Market Share Comparison, By Region

4.1.4.3. Y-o-Y growth Comparison, By Region

5. Global Laser Therapy Devices Market Analysis and Forecast By Application

5.1. Global Laser Therapy Devices Market Size and Forecast By Application, 2012-2022

5.1.1. Opthalmology Market Size and Forecast, 2012-2022

5.1.1.1. Revenue (US$ Mn) Comparison, By Region

5.1.1.2. Market Share Comparison, By Region

5.1.1.3. Y-o-Y growth Comparison, By Region

5.1.2. Dermatology Market Size and Forecast, 2012-2022

And So On

Explore Wide-ranging Coverage of FMIsHealthcareMarket Insights Landscape

Rib Fracture Repair Systems Market FMIs analysis gives an insight into key market trends, strategies, regional players and various segments on the basis of form, type, application and region.

Ovulation Test Kit Market Find insights into global market scenario and segmentation on the basis of ingredients, application, source and region.

Radiometric Detectors Market FMIs report highlights parent market trends and strategies in the market with segments and dynamics through the forecast period.

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries.FMIis headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMIs latestmarket research reportsand industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Mr. Abhishek BudholiyaUnit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,Jumeirah Lakes Towers, Dubai,United Arab EmiratesMARKET ACCESS DMCC InitiativeFor Sales Enquiries:sales@futuremarketinsights.comFor Media Enquiries:press@futuremarketinsights.com

Read more:
Laser Therapy Devices Market In-Depth Analysis, Growth Strategies and Comprehensive Forecast to 2022 - PharmiWeb.com

Opthalmology Pacs Market Report, published by Adroit Market Research, provides an industry assessment of the Opthalmology Pacs market covering the most important factors driving the growth of the Opthalmology Pacs industry. Opthalmology Pacss latest market research report contains an extensive analysis of micro and macroeconomic indicators affecting the development of the global market in the forecast period 2021-2027.

The current trends of the Opthalmology Pacs market, combined with broad growth opportunities, key drivers, constraints, challenges and other important aspects, are detailed in the Opthalmology Pacs market report. Additionally, the report makes many development prospects for key players involved in the Opthalmology Pacs industry taking into account various market dynamics.

Get PDF Sample Report of Opthalmology Pacs (COVID-19 Version) Market 2021, Click Here @ https://www.adroitmarketresearch.com/contacts/request-sample/608?utm_source=Pa

Overview of the Opthalmology Pacs Report:

The Opthalmology Pacs market has been broadly segmented to allow readers a deeper understanding of the different aspects and attributes of the market. The market size of new entrants and existing companies was assessed using a variety of analytical tools including SWOT analysis, investment assessment, and Porters Five Forces Analysis. Additionally, as part of the study, report authors assessed the financial position of leading companies operating in the industry. They provided important insights into gross profit margin, revenue sharing, sales volume, operating costs, individual growth rates, and many other financial metrics of these competitors.

Some of the Important and Key Players of the Global Opthalmology Pacs Market:

Topcon Corporation, IBM corporation, Carl Zeiss Meditec AG, EyePACS, Heidelberg Engineering and more.

Get a copy here: https://www.adroitmarketresearch.com/industry-reports/opthalmology-pacs-market?utm_source=Pa

Opthalmology Pacs market report comprises an in-depth valuation in regards to the future advancements relying on the past data and present circumstance of Opthalmology Pacs market. It provides holistic view on market to take wise decisions regarding future opportunities. Research team has investigated principals, key players in the market, geographical fragmentation, product type and its description, and market end-client applications. It provides estimated sales revenue from each and every segment along with for each region. Opthalmology Pacs Market report comprises of primary and secondary data which is presented in the form of graphs and pie charts for better understanding. The overall report is presented in an effective manner that involves basic dialect, basic outline, agreements, and certain facts as per consolation and comprehension.

Opthalmology Pacs Market Segmentation

Type Analysis of Opthalmology Pacs Market:

By End-Use, market is segmented into:

HospitalsAmbulatory Surgical Center (ASCS) & Specialty ClinicsOthersBy Type, market is segmented into:

Standalone PACSIntegrated PACSBy Delivery Model, market is segmented into:

Cloud/ web based modelsOn-premise modelsOthers

The Geographical Landscape of the Market Include:

1.The research offers an analysis of the geographical landscape of the Opthalmology Pacs Market, which is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. It includes data about several parameters related to the regional contribution.2.The study provides information regarding the sales generated through each region and the registered market share.3.Information related to the growth rate during the forecast period is included in the report. The Opthalmology Pacs Market report claims that the industry is projected to generate significant revenue during the forecast period. It consists of information related to the market dynamics such as challenges involved in this vertical, growth opportunities, and factors affecting the market.

What key bits of knowledge does the Opthalmology Pacs statistical surveying give?

1.Past and current income insights of the Opthalmology Pacs market players investigated at local level.2.Individual profiling of significant partners.3.Analysis of the Opthalmology Pacs market size based on item type and end use type.4.Accurate Opthalmology Pacs market estimate in numbers and percent rates.5.Demand prospect of individual sections shrouded in the Opthalmology Pacs report.

For More Information on this report, Request Inquiry : https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/608?utm_source=Pa

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 210-667-2421/ +91 9665341414

Read the rest here:
Opthalmology Pacs Market 2021, by Types of Sports, Revenue, Demand, Emerging Trends, Regional Events, and Investment Opportunities to 2026 | Topcon...

Adroit Market Research provides you global research analysis on Opthalmology Pacs Market and forecast to 2027. The research report provides deep insights into the global market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The Opthalmology Pacs market report is a comprehensive study of various trends and affecting factors of the Opthalmology Pacs Industry. These variables have helped decide the behavior of the market during the forecast period of 2021-2026 and empowered our specialists to make effective and precise predictions about the market future. The primary data for Opthalmology Pacs Market has been collected from multiple trustworthy sources like journals, websites, white papers, annual reports of the businesses, and mergers. to form better decisions, generate maximum revenue, and enhance business profit, this market research report may be a great solution. This study helps to provides a detailed overview of the present scenario of the global market, latest updates, product launches, joint ventures, capacity, production value, mergers, and acquisitions supported several market dynamics.

Get Exclusive Sample of Report on Opthalmology Pacs market is available @ https://www.adroitmarketresearch.com/contacts/request-sample/608?utm_source=PT

Global Opthalmology Pacs Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to Opthalmology Pacs Industry.

The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Opthalmology Pacs market. The researcher provides an extensive analysis of the Opthalmology Pacs market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market. The report specifically highlights the market share, company profiles, regional outlook, product portfolio, a record of the recent developments, strategic analysis, key players in the market, sales, distribution chain, manufacturing, production, new market entrants as well as existing market players, advertising, brand value, popular products, demand and supply, and other important factors related to the market to help the new entrants understand the market scenario better.

Top Leading Key Players are:

Topcon Corporation, IBM corporation, Carl Zeiss Meditec AG, EyePACS, Heidelberg Engineering and more.

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/opthalmology-pacs-market?utm_source=PT

The main players in the Opthalmology Pacs market are studies, and their strategies which are analyzed to arrive at current growth strategies, and potential for expansion. Additionally, the competitive landscape is because of the presence of market suppliers, numerous sales channels, and revenue options. The market document holds substantial importance when it is about explaining the market definition, classifications, applications, and engagements. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, the scope of New Product Development [NPD] in new markets, pricing strategies, innovation possibilities, and much more.

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Opthalmology Pacs market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Opthalmology Pacs markets trajectory between forecast periods.

Global Opthalmology Pacs market is segmented based by type, application and region.Based on Type, the market has been segmented into:

By End-Use, market is segmented into:

HospitalsAmbulatory Surgical Center (ASCS) & Specialty ClinicsOthersBy Type, market is segmented into:

Standalone PACSIntegrated PACSBy Delivery Model, market is segmented into:

Cloud/ web based modelsOn-premise modelsOthers

Highlights of the report:1. A complete backdrop analysis, which includes an assessment of the parent market2. Important changes in market dynamics3. Market segmentation up to the second or third level4. Historical, current, and projected size of the market from the standpoint of both value and volume5. Reporting and evaluation of recent industry developments6. Market shares and strategies of key players7. Emerging niche segments and regional markets8. An objective assessment of the trajectory of the market9. Recommendations to companies for strengthening their foothold in the market

Points Covered in the Report: The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc. The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 12 years data history and forecast. The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail. Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements. The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Table of Contents:1.Opthalmology Pacs Market Overview2.Global Economic Impact on Industry3.Global Opthalmology Pacs Market Competition by Manufacturers4.Global Production, Revenue (Value) by Region5.Global Supply (Production), Consumption, Export, Import by Regions6.Global Production, Revenue (Value), Price Trend by Type7.Global Opthalmology Pacs Market Analysis by Application8.Manufacturing Cost Analysis9.Industrial Chain, Sourcing Strategy, and Downstream Buyers10.Marketing Strategy Analysis, Distributors/Traders11.Market Effect Factors Analysis12.Global Opthalmology Pacs Market Forecast

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/608?utm_source=PT

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

More here:
Opthalmology Pacs Market 2020 Trends, Growth Insight, Share, Competitive Analysis, Statistics, Regional and Global Industry Forecast To 2025 ...

Adroit Market Research published a new research report of Global Opthalmology Pacs Market 2020-2026 presents a widespread and elementary study of the market including key business insights and the analysis of subjective views related to the market. The global Opthalmology Pacs market report examines the market position and viewpoint of the market worldwide, from various angles, such as from the key players point, geological regions, types of product and application. This Opthalmology Pacs report highlights the key driving factors, constraint, opportunities, challenges in the competitive market. It also offers thorough Opthalmology Pacs analysis on the market stake, classification, and revenue projection. The Opthalmology Pacs market report delivers market status from the readers point of view, providing certain market stats and business intuitions. The global Opthalmology Pacs industry includes historical and futuristic data related to the industry. It also includes company information of each market player, capacity, profit, Opthalmology Pacs product information, price, and so on.

The report includes the most important industry information while highlighting vital and valuable data. The report provides learning of various factors such as Opthalmology Pacs market growth, consumption volume, market trends, and business price structures throughout the forecast amount from 2020 to 2026. A detailed study report is accessible for the beneficial of audience and stakeholders. It studies the market dynamic factors including the drivers, restraints, trends, and opportunities of the global market. The report also analyze the competitive landscape of the business. Opthalmology Pacs Market is growing at high CAGR during the forecast period 20212027. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get the PDF Sample Copy of this report @ https://www.adroitmarketresearch.com/contacts/request-sample/608?utm_source=PT

Highlights of The Global Opthalmology Pacs Market Report: A clear understanding of the Opthalmology Pacs market supported growth, constraints, opportunities, encountered challenges, technological advancements, practicable study. The market review for the global market is done in context to region, share, and size. Analysis of evolving market segments in addition to a complete study of existing market segments. The performance of the market throughout 2020-2026 is being forecasted during this report. The data has been categorized and summarized based on types, regions, companies, and applications of the product. The report has examined cutthroat developments such as agreements, expansions, new product launches, and mergers in the market

Global Opthalmology Pacs market is segmented based by type, application and region.Based on Type, the market has been segmented into:

By End-Use, market is segmented into:

HospitalsAmbulatory Surgical Center (ASCS) & Specialty ClinicsOthersBy Type, market is segmented into:

Standalone PACSIntegrated PACSBy Delivery Model, market is segmented into:

Cloud/ web based modelsOn-premise modelsOthers

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/opthalmology-pacs-market?utm_source=PT

Top Leading Key Players are:

Topcon Corporation, IBM corporation, Carl Zeiss Meditec AG, EyePACS, Heidelberg Engineering and more.

This detailed report also highlights key insights on the factors that drive the growth of the market as well key challenges that are expected to hamper the market growth in the forecast period. Keeping a view to provide a holistic market view, the report describes the market components such as product types and end users in details with explaining which component is expected to expand significantly and which region is emerging as the key potential destination of the Opthalmology Pacs market. Moreover, it provides a critical assessment of the emerging competitive landscape of the manufacturers as the demand for the Opthalmology Pacs is projected to increase substantially across the different regions.

Key Questions Answered in the Report:1. What is the size of the overall Opthalmology Pacs market and its segments?2. What are the key segments and sub-segments in the market?3. What are the key drivers, restraints, opportunities and challenges of the Opthalmology Pacs market and how they are expected to impact the market?4. What are the attractive investment opportunities within the Market?5. What is the Opthalmology Pacs market size at the regional and country-level?6. Who are the key market players and their key competitors?7. Market value- chain and key trends impacting every node with reference to companies8. What are the strategies for growth adopted by the key players in Opthalmology Pacs market?9. How does a particular company rank against its competitors with respect to revenue, profit comparison, operational efficiency, cost competitiveness and market capitalization?10. How financially strong are the key players in Opthalmology Pacs market (revenue and profit margin, market capitalization, expenditure analysis, investment analysis)?11. What are the recent trends in Opthalmology Pacs market? (M&A, partnerships, new product developments, expansions)

Table of Content:1. Industry Overview of Opthalmology Pacs.2. Manufacturing Cost Structure Analysis of Opthalmology Pacs market.3. Specialized Information and Manufacturing Plants Investigation of Opthalmology Pacs.4. Capacity, Production and Revenue Analysis.5. Price, Cost, Gross and Gross Margin Analysis of Opthalmology Pacs by Regions, Types and Manufacturers.6. Consumption Volume, Consumption Value and Sale Price Analysis of Opthalmology Pacs industry by Regions, Types and Applications.7. Supply, Import, Export and Consumption Analysis of Opthalmology Pacs Market.8. Major Manufacturers Analysis of Opthalmology Pacs industry.9. Marketing Trader or Distributor Analysis of Opthalmology Pacs.10. Industry Chain Analysis of Opthalmology Pacs.11. Development Trend Analysis of Opthalmology Pacs Market.12. New Project Investment Feasibility Analysis of Opthalmology Pacs.13. Conclusion of the Opthalmology Pacs Industry.

For Any Query on the Opthalmology Pacs Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/608?utm_source=PT

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read the rest here:
Opthalmology Pacs Market Global Innovations, Competitive Analysis, New Business Developments and Top Companies Global Forecast to 2026 - LionLowdown

Milestone Scientific Inc (NYSEAMERICAN: MLSS) is a medical device research and development (R&D) group.

It designs and patents innovative injection technology and specializes in dynamic pressure sensing, which allows medics to know what the pressure at the tip of needle is at any time.

The company is advancing computer-controlled drug delivery systems that offer significant efficiency and patient comfort gains in the medical and dentistry fields.

Its wand product for dentistry, which is the group's biggest revenue earner, makes an injection at the dentist a lot more comfortable. The numbness is contained on a single tooth rather than a whole portion of the mouth.

In the medical solutions space, the firm has a CompuFlo Epidural Instrument for epidural injections, which has a 99% success in locating the epidural space on the first attempt. Done manually, the procedure can be cumbersome and time-consuming. The company believes the epidural system will become the new standard of care.

The addition to the system (for catheter patients) is its CathCheck technology which is also gaining traction.

Milestone also has a Compuflo training product to help medical students master epidurals. Milestone's CompuFlo Intra-Articular Instrument has been proven successful in administering medicaments into the intra-articular space.

The group is also looking at future products in the cosmetic surgery, opthalmic and neurosurgical sectors.

In a statement at the end of November, the group's president Arjan Haverhals said the firm's dental business continued to recover and he saw growth in dental sales during the fourth quarter of 2020.

"While we are not back to pre-pandemic levels, I am pleased to report our sales continue trending in the right direction and we anticipate revenue in the fourth quarter of 2020 to be a minimum of $1.7 million," he said.

Haverhals said such a haul in revenue would represent a 40% sequential increase versus the 3Q, which follows a 718% increase for the 3Q compared to the 2Q of 2020. And this does not include recent sales to the companys Chinese distributor of about $450,000, which will be recorded as revenue when the inventory is resold by the distributor.

We are encouraged by the current trends in both the USA and around the world, which has improved our cash flow and provides us greater financial stability along with the necessary funds for marketing and sales to continue the growth in the dental sector, he told investors.

Earlier last month, the group posted third quarter financials (to September 30), which showed revenue of $1.2 million compared to the $1.9 million it posted in the same quarter in 2019. The net loss was narrowed to $1.5 million, or $0.02 per share, versus the $2.8 million, or $0.06 a share, it posted in the comparable year-ago quarter.

In October, Milestone was awarded a group purchasing agreement with Premier, a leading group purchasing organization, with around 4,100 US hospitals and 200,000 other providers within its network.

Milestoneis also expanding its trials in major hospitals and medical schools and partnering with key opinion leaders to approach the purchasing departments of hospitals together

The company ended the three-month period with over $14 million of cash on hand, which will support marketing and other ongoing activities, it added.

President Arjan Haverhals spoke to Proactive in November this year and said the company was in good financial shape with no plans to raise capital in the short, or mid-term.

"With the cash at hand, the recovery of the dental business, we have a burn rate of about US$320,000 per quarter, and hen also with the anticipated sales of the CompuFlow, the epidural system, and the CathCheck, we really look forward to become cash positive next year."

Contact the author at [emailprotected]

The rest is here:
Milestone Scientific, the pressure sensing specialist, has cash in bank and eyeing growing dental sales - Proactive Investors USA & Canada

In a bid to give access to health services to people belonging to every strata of the society, December 12 is celebrated as the Universal Health Coverage Day all across the world. The theme of 2020 is Health for all: protect everyone. To end this crisis and build a safer and health systems that protect us all now. Ayushman Bharat Pradhan Mantri Jan Arogya Yojana is the Government of Indias attempt in the direction of Universal Health Coverage and it bridges the gender gap by providing access to healthcare services to women. It is to be noted that of all the hospital admissions, 49.8% of the treatment(insights.pmjay.gov.in) hasbeen availed by women.

The 2018 Gender Gap Index of the World Economic Forum and its sub-index, Health and Survival ranked India at 108th position in the overall index and 147th out of 149 in the sub-index. Here is how Ayushman Bharat PM-JAY is empowering women in accessing healthcare services

* Families with no adult male members is one of the deprivation criteria foridentifying target beneficiaries, which will ensure the reach of the scheme to a large number of women.

* Cap of five beneficiaries from a family in earlier schemes worked against women. It was seen that families prefer to prioritise the male members over females, excluding them from availing free health care benefits. Ayushman Bharat PM-JAY does not have any ceiling on number of family members hence the right to free healthcare under the scheme is being equally exercised by male and female members of the family.

* Being a man or a woman has significant impact on health due to biological and gender related differences. The packages include a large number of health conditions that exclusively, or primarily, affect women.

* Under Ayushman Bharat, individual e-cards are being issued which gives every female beneficiary an individual sense of entitlement to claim their right to free healthcare.

Women-specific DATA points:

* Top 5 states, where women are availing higher number of treatments:

1. Tamil Nadu

2. Kerala

3. Chhattisgarh

4. Karnataka

5. Andhra Pradesh

* Top 5 specialities availed by women:

1. General Medicine

2. Obstetrics & Gynaecology

3. General Surgery

4. Medical Oncology

5. Opthalmology

6. Infectious Diseases

A lot of beneficiaries feel grateful to have been given a new lease on life and resident of Gurgaon, Santosh is one of them. Aged 44, she, her three children and her ageing in-laws were all dependent on her husband, whose sudden demise further threw the family into distress. Santosh took up the baton, where her husband left off and filled the void. The family slowly began healing and on the road to recovery. Just when things were getting back to normal, Santosh noticed that she was finding it hard to climb up and down the stairs.

However, a sense of sacrifice and service prevented her from doing anything about it. Besides, she did not want to cause anxiety in the family again. She continued as if nothing had happen, hiding her pain and discomfort and turning a blind eye to her condition.

Soon, she got to know about Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY); Haryana Health Protection Mission and the various benefits that were available under this health scheme. Since, her pain was becoming unbearable, she decided to go to a hospital and get checked. She found out that she had two blocked valves in her heart and needed immediate surgery. This timely intervention truly saved her and helped her secure the future of her children.

Besides bridging gender gap, PM JAY has been immensely successful in providinghealthcare services to the needy. As per the latest government data, 1.4 crore cashless treatments worth INR. 17, 535 crores across 24,653 (Public: Private = 54:46) empaneled hospitals have been approved under the scheme. Also, the scheme is at the forefront of battling the pandemic right now. Currently, the COVID 19 testing and treatment numbers are 10,23,651.

See Zee Business Live TV Streaming Below:

Read the rest here:
Universal Health Coverage Day: Nearly 50% of the treatments under PMJAY are availed by women! - Zee Business